德林控股(01709.HK)管理基金斥100萬美元投資新加坡科技公司Pangu Software
德林控股(01709.HK)宣布,集團全資附屬所管理的私募基金於8月4日與新加坡科技公司Pangu Software 訂立認購協議,該基金將以總代價100萬美元認購1,041股普通股,並獲得以同等條件追加認購1,041股的認購期權。完成投資後,基金將持有Pangu約2%股權。
Pangu專門開發去中心化的Web3遊戲平台,利用區塊鏈技術和人工智能技術提高用戶參與度、數字資產所有權以及創新的遊戲盈利模式。
目前,德林控股於該基金擁有約11.7%權益。集團預期是次投資切合集團在數字金融、虛擬資產和現實世界資產(RWA)代幣化方面的業務發展計劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.